FOXP3 As an X-linked Tumor Suppressor

Overview

Journal Discov Med

Specialty General Medicine

Date 2010 Nov 2

PMID 21034673

Citations 17

Authors

Lizhong Wang

Runhua Liu

Mark Ribick

Pan Zheng

Yang Liu

Affiliations

Soon will be listed here.

Abstract

The FOXP3 gene was initially identified because its mutation caused lethal autoimmune diseases in mice and humans. Mice with heterozygous mutations of FoxP3 (mouse version of the FOXP3 gene) succumb to mammary tumors spontaneously, while those with prostate-specific deletions develop prostate intraepithelial neoplasia. Somatic mutations, deletion, and epigenetic inactivation of FOXP3 are widespread among human breast and prostate cancers. Unlike autosomal tumor suppressor genes that are usually inactivated by mutations in both alleles, X-linked FOXP3 mutations in cancer samples are usually heterozygous, with the wildtype allele selectively inactivated in cancer. This skewed X-inactivation suggests a new approach to reactivation of FOXP3 for cancer therapy.

Citing Articles

A Case Report of IPEX Syndrome with Neonatal Diabetes Mellitus and Congenital Hypothyroidism as the Initial Presentation, and a Systematic Review of neonatal IPEX.

Hou A, Wang Y, Pan Y J Clin Immunol. 2023; 43(5):979-988.

PMID: 36867340 DOI: 10.1007/s10875-023-01456-0.

The Role of FOXP3 on Tumor Metastasis and Its Interaction with Traditional Chinese Medicine.

Ma B, Miao W, Xiao J, Chen X, Xu J, Li Y Molecules. 2022; 27(19).

PMID: 36235242 PMC: 9570879. DOI: 10.3390/molecules27196706.

Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer.

Brunty S, Clower L, Mitchell B, Fleshman T, Bou Zgheib N, Santanam N Front Oncol. 2021; 11:793297.

PMID: 34900746 PMC: 8655857. DOI: 10.3389/fonc.2021.793297.

The role of FOXP3 rs3761548 and rs2294021 polymorphisms in pediatrics acute lymphoblastic leukemia: association with risk and response to therapy.

Ghasemi Z, Kalantar K, Amirghofran Z Mol Biol Rep. 2021; 48(2):1139-1150.

PMID: 33517519 DOI: 10.1007/s11033-021-06154-x.

The multifaceted Foxp3 allele enhances spontaneous and therapeutic immune surveillance of cancer in mice.

Almeida-Santos J, Bergman M, Cabral I, Correia V, Caramalho I, Demengeot J Eur J Immunol. 2019; 50(3):439-444.

PMID: 31729760 PMC: 7078871. DOI: 10.1002/eji.201948251.

References

Wang L, Liu R, Li W, Chen C, Katoh H, Chen G . Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009; 16(4):336-46. PMC: 2758294. DOI: 10.1016/j.ccr.2009.08.016. View

Merlo A, Casalini P, Carcangiu M, Malventano C, Triulzi T, Menard S . FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009; 27(11):1746-52. DOI: 10.1200/JCO.2008.17.9036. View

Cheng P, Gosewehr J, Kim T, Velicescu M, Wan M, Zheng J . Potential role of the inactivated X chromosome in ovarian epithelial tumor development. J Natl Cancer Inst. 1996; 88(8):510-8. DOI: 10.1093/jnci/88.8.510. View

Chen G, Chen C, Wang L, Chang X, Zheng P, Liu Y . Cutting edge: Broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. J Immunol. 2008; 180(8):5163-6. PMC: 2527697. DOI: 10.4049/jimmunol.180.8.5163. View

Brunkow M, Jeffery E, Hjerrild K, Paeper B, Clark L, Yasayko S . Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001; 27(1):68-73. DOI: 10.1038/83784. View

Ebert L, Tan B, Browning J, Svobodova S, Russell S, Kirkpatrick N . The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res. 2008; 68(8):3001-9. DOI: 10.1158/0008-5472.CAN-07-5664. View

Chenevix-Trench G, Kerr J, Hurst T, Shih Y, Purdie D, Bergman L . Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations. Genes Chromosomes Cancer. 1997; 18(2):75-83. DOI: 10.1002/(sici)1098-2264(199702)18:2<75::aid-gcc1>3.0.co;2-y. View

Katoh H, Zheng P, Liu Y . Signalling through FOXP3 as an X-linked tumor suppressor. Int J Biochem Cell Biol. 2010; 42(11):1784-7. PMC: 2950213. DOI: 10.1016/j.biocel.2010.07.015. View

Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D . Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 1998; 20(2):175-9. DOI: 10.1038/2477. View

10.

Sirchia S, Ramoscelli L, Grati F, Barbera F, Coradini D, Rossella F . Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells. Cancer Res. 2005; 65(6):2139-46. DOI: 10.1158/0008-5472.CAN-04-3465. View

11.

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

12.

Bennett C, Christie J, Ramsdell F, Brunkow M, Ferguson P, Whitesell L . The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27(1):20-1. DOI: 10.1038/83713. View

13.

Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W . FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007; 129(7):1275-86. PMC: 1974845. DOI: 10.1016/j.cell.2007.04.034. View

14.

Yang-Feng T, Li S, Han H, Schwartz P . Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int J Cancer. 1992; 52(4):575-80. DOI: 10.1002/ijc.2910520414. View

15.

Wang N, Cedrone E, Skuse G, Insel R, Dry J . Two identical active X chromosomes in human mammary carcinoma cells. Cancer Genet Cytogenet. 1990; 46(2):271-80. DOI: 10.1016/0165-4608(90)90112-n. View

16.

Buekers T, Lallas T, Buller R . Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer. Gynecol Oncol. 2000; 76(3):418-22. DOI: 10.1006/gyno.1999.5713. View

17.

Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F . Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2010; 125(1):65-72. DOI: 10.1007/s10549-010-0831-1. View

18.

Choi C, Cho S, Horikawa I, Berchuck A, Wang N, Cedrone E . Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. Genes Chromosomes Cancer. 1997; 20(3):234-42. View

19.

Gudmundsson J, Sulem P, Rafnar T, Bergthorsson J, Manolescu A, Gudbjartsson D . Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008; 40(3):281-3. PMC: 3598012. DOI: 10.1038/ng.89. View

20.

Lange E, Chen H, Brierley K, Perrone E, Bock C, Gillanders E . Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin Cancer Res. 2000; 5(12):4013-20. View